$5.04
Applied DNA Sciences
Performance
Dividends
-96.6%
1W
1M
YTD
1Y
3Y
16/36
Growth Score
13/36
Dividend Score
Valuation
PE Ratio
-0.29
PS Ratio
0.69
RSI
-
0
PEG Ratio
-0.24
0
PRG Ratio
-0.04
PDG Ratio
0
Growth
0-26%0-74%351%340%
-20%29%89%77%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
91.39%
1
Gross Margin
40.76%
3
Current Ratio
4.45
Return on Assets
-239.96%
Return on Equity
-281.09%
Return on inv. Capital
-693.88%
Institutional Holder
204.3960100.354
234
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 3.43M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -7.09M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 1.02M
2018
2019
2020
2021
2022
2023
2024
6
Events
APDN
Applied DNA Sciences
in 292 days
after market close
Earnings per Share is expected with - and revenue with - .
APDN
Applied DNA Sciences
in 201 days
after market close
Earnings per Share is expected with - and revenue with - .
APDN
Applied DNA Sciences
in 143 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Diagnostics & Research
IPO Date
15.07.2003
MaketCap
2.62M
Country
US
CEO
James A. Hayward Sc.D.
Description
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Updated 19.07.2025